{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T05:32:50Z","timestamp":1706851970313},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1208\/s12248-021-00607-8","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T21:02:39Z","timestamp":1623099759000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)"],"prefix":"10.1208","volume":"23","author":[{"given":"Oliver","family":"Ackaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"P\u00e9rez-Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"P\u00e9rez-Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herta M.","family":"Crauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"1","key":"607_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","volume":"14","author":"C Orkin","year":"2013","unstructured":"Orkin C, DeJesus E, Khnlou H, Stoehr A, Supparatpinyo K, Lathouwers E, et al. Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial. HIV Med. 2013;14(1):49\u201359.","journal-title":"HIV Med."},{"issue":"7","key":"607_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","volume":"25","author":"P Cahn","year":"2011","unstructured":"Cahn P, Fourie J, Grinsztejn B, Molina JM, Ruxrungtham K, Workman C, et al. Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929\u201339.","journal-title":"AIDS."},{"issue":"9","key":"607_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/INF.0000000000000308","volume":"33","author":"P Flynn","year":"2014","unstructured":"Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S, et al. Efficacy and safety of darunavir\/ritonavir at 48 weeks in treatment-na\u00efve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). Pediatr Infect Dis J. 2014;33(9):940\u20135.","journal-title":"Pediatr Infect Dis J."},{"issue":"5\u20136","key":"607_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/15284336.2017.1387690","volume":"18","author":"E Lathouwers","year":"2017","unstructured":"Lathouwers E, Wong EY, Luo D, Seyedkazemi S, De Meyer S, Brown K. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials. 2017;18(5\u20136):196\u2013204.","journal-title":"HIV Clin Trials."},{"issue":"11","key":"607_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","volume":"32","author":"J Eron","year":"2018","unstructured":"Eron J, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, et al. A week 48 randomized phase 3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve HIV-1 patients. AIDS. 2018;32(11):1431\u201342.","journal-title":"AIDS."},{"issue":"1","key":"607_CR6","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin C, Molina J-M, Negredo E, Arribas JR, Gathe J, Eron JJ, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once-daily complete HIV-1 regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in virologically suppressed, HIV-1-infected adults through 48 weeks (EMERALD): a phase 3, randomized, non-inferiority trial. Lancet HIV. 2018;5(1):e23\u201334.","journal-title":"Lancet HIV."},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"104543","DOI":"10.1016\/j.antiviral.2019.104543","volume":"170","author":"J Eron","year":"2019","unstructured":"Eron J, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res. 2019;170:104543.","journal-title":"Antiviral Res."},{"issue":"5","key":"607_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/QAD.0000000000002463","volume":"34","author":"C Orkin","year":"2020","unstructured":"Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, et al. Week 96 results of a phase 3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve HIV-1 patients. AIDS. 2020;34(5):707\u201318.","journal-title":"AIDS."},{"key":"607_CR9","unstructured":"Janssen-Cilag International NV. SYMTUZA\u00ae (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets Summary of Product Characteristics. 2017. Revised: July 2019. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/8430. Accessed 20 Oct 2020."},{"key":"607_CR10","unstructured":"Janssen Pharmaceutical Companies. Prescribing information for SYMTUZA\u00ae (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets. 2018. Revised: March 2020. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SYMTUZA-pi.pdf. Accessed 20 Oct 2020."},{"key":"607_CR11","unstructured":"EACS. European AIDS Clinical Society guidelines. Version 10.1. 2020. Available from: https:\/\/www.eacsociety.org\/files\/guidelines-10.1.finalsept2020.pdf. Accessed 20 Oct 2020."},{"key":"607_CR12","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. Available from: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed 20 Oct 2020."},{"issue":"16","key":"607_CR13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651\u201369.","journal-title":"JAMA."},{"issue":"4","key":"607_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/dmd.108.024109","volume":"37","author":"M Vermeir","year":"2009","unstructured":"Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009;37(4):809\u201320.","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"607_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1586\/14787210.2015.1033400","volume":"13","author":"TN Kakuda","year":"2015","unstructured":"Kakuda TN, Crauwels H, Opsomer M, Tomaka F, van de Casteele T, Vanveggel S, et al. Darunavir\/cobicistat once daily for the treatment of HIV. Expert Rev Anti Infect Ther. 2015;13(6):691\u2013704.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3851\/IMP2814","volume":"19","author":"TN Kakuda","year":"2014","unstructured":"Kakuda TN, Van De Casteele T, Petrovic R, Neujens M, Salih H, Opsomer M, et al. Bioequivalence of a darunavir\/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther. 2014;19:597\u2013606.","journal-title":"Antivir Ther."},{"issue":"8","key":"607_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/jcph.290","volume":"54","author":"TN Kakuda","year":"2014","unstructured":"Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T, Hillewaert V, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54(8):949\u201357.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"607_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/mol.108.045526","volume":"74","author":"G Birkus","year":"2008","unstructured":"Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008;74(1):92\u2013100.","journal-title":"Mol Pharmacol."},{"issue":"5","key":"607_CR19","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","volume":"49","author":"WA Lee","year":"2005","unstructured":"Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898\u2013906.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"607_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","volume":"69","author":"A Mills","year":"2015","unstructured":"Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439\u201345.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"4","key":"607_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Syndr. 2013;63(4):449\u201355.","journal-title":"J Acquir Immune Syndr."},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1\u20137.","journal-title":"Biochem Pharmacol."},{"issue":"4","key":"607_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/cpdd.628","volume":"8","author":"HM Crauwels","year":"2019","unstructured":"Crauwels HM, Baugh B, Van Landuyt E, Vanveggel S, Hijzen A, Opsomer M. Bioequivalence of the once-daily single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide compared to combined intake of the separate agents and the effect of food on bioavailability. Clin Pharmacol Drug Dev. 2019;8(4):480\u201391.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"4","key":"607_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","volume":"78","author":"R Begley","year":"2018","unstructured":"Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of tenofovir alafenamide when co-administered with other HIV antiretrovirals. J Acquir Immune Defic Syndr. 2018;78(4):465\u201372.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"607_CR25","unstructured":"Vis P, Sekar V, van Schaik E, Hoetelmans R. Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects after administration of TMC114 in combination with low-dose ritonavir. 15th Annual Meeting of the Population Approach Group in Europe, 14\u201316 June 2006, Bruges, Belgium. Abstract 964. Available from: www.page-meeting.org\/?abstract=964. Accessed 20 Oct 2020."},{"issue":"7","key":"607_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/psp4.44","volume":"4","author":"A Brochot","year":"2015","unstructured":"Brochot A, Kakuda TN, Van De Casteele T, Opsomer M, Tomaka FL, Vermeulen A, et al. Model-based once-daily darunavir\/ritonavir dosing recommendations in pediatric HIV-1-infected patients aged \u22653 to <12 Years. CPT Pharmacometrics Syst Pharmacol. 2015;4(7):406\u201314.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"607_CR27","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2020. Available from: http:\/\/www.R-project.org\/ and http:\/\/cran.r-project.org\/. Accessed 01 Jul 2020."},{"key":"607_CR28","unstructured":"Kakuda TN, Brochot A, Custodio JM, Green B, Vanveggel S, Van De Casteele T, et al. Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130. 15th International Workshop on Clinical Pharmacology of HIV Therapy. May 19\u201321, 2014. Abstract\/poster P_49."},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1742-6405-11-39","volume":"11","author":"K Tashima","year":"2014","unstructured":"Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Van De Casteele T, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.","journal-title":"AIDS Res Ther."},{"issue":"2","key":"607_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometr Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"3","key":"607_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009 Sep;11(3):558\u201369.","journal-title":"AAPS J."},{"issue":"6","key":"607_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1310\/hct1206-313","volume":"12","author":"J Fourie","year":"2011","unstructured":"Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir\/ ritonavir in HIV-1-infected, treatment-na\u00efve ARTEMIS patients at week 96. HIV Clin Trials. 2011 Nov-Dec;12(6):313\u201322.","journal-title":"HIV Clin Trials."},{"key":"607_CR33","unstructured":"Sekar VJ, De Paepe E, Van Baelen B et al. Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir\/ritonavir (DRV\/r) in HIV-1 patients: results of a randomised, controlled, Phase III study (TITAN). Abstracts of the Eleventh European AIDS Conference, Madrid, 2007. Abstract PS4\/5"},{"issue":"7","key":"607_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/hiv.12024","volume":"14","author":"M Sension","year":"2013","unstructured":"Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, et al. Subgroup analysis of virological response rates with once- and twice-daily darunavir\/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. HIV Med. 2013 Aug;14(7):437\u201344.","journal-title":"HIV Med."},{"key":"607_CR35","first-page":"186987","volume":"2012","author":"T Kakuda","year":"2012","unstructured":"Kakuda T, Sekar V, Vis P, Coate B, Ryan R, Anderson D, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the gender, race, and clinical experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987.","journal-title":"AIDS Res Treat."},{"issue":"10","key":"607_CR36","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1128\/AAC.01089-12","volume":"56","author":"EI Lepist","year":"2012","unstructured":"Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409\u201313.","journal-title":"Antimicrob Agents Chemother."},{"key":"607_CR37","unstructured":"Ramanathan S, Custodio J, Wang H, Dave A, Cheng A, Kearney B. Pharmacokinetics of a novel EVG\/COBI\/TFC\/GS-7340 single tablet regimen. 13th International Workshop on Clinical Pharmacology of HIV Therapy. April 16\u201318, 2012. Abstract O_13."},{"issue":"Suppl 1","key":"607_CR38","first-page":"Abstract PI_044","volume":"97","author":"JM Custodio","year":"2015","unstructured":"Custodio JM, Wang H, Silva A, Zhong L, Zack JZ, Callebaut C, et al. Drug interaction potential of emtricitabine (F; FTC)\/tenofovir (TFV) alafenamide (TAF) (F\/ TAF) fixed dose combination and cobicistat (COBI)-boosted darunavir (DRV). Clin Pharmacol Ther. 2015;97(Suppl 1):Abstract PI_044.","journal-title":"Clin Pharmacol Ther"},{"key":"607_CR39","unstructured":"Gilead Sciences. Prescribing information: VEMLIDY\u00ae (tenofovir alafenamide). Foster City, California, 2016. Available at: https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/vemlidy\/vemlidy_pi.pdf?la=en"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00607-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T15:15:54Z","timestamp":1629299754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00607-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oliver Ackaert, Carlos P\u00e9rez-Ruixo, Juan Jose P\u00e9rez-Ruixo, John Jezorwski\u00a0and Herta Crauwels are all full-time employees of Janssen and potential stockholders of Johnson and Johnson. David McDougall was a paid consultant by Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"82"}}